Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Q4 Medicine

Forum of Clinical Oncology Pub Date : 2021-05-01 DOI:10.2478/fco-2019-0021

Heba F. Taha, O. Elfarargy, R. Salem, Doaa Mandour, A. Salem, Mohamed Riad

{"title":"Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer","authors":"Heba F. Taha, O. Elfarargy, R. Salem, Doaa Mandour, A. Salem, Mohamed Riad","doi":"10.2478/fco-2019-0021","DOIUrl":null,"url":null,"abstract":"Abstract Background Introducing neoadjuvant chemotherapy (NCT) in a breast cancer patient may be associated with changes in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth hormone receptor 2 (HER2) status. Patients and methods In our prospective cohort study, we evaluated the impact of change in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth hormone receptor 2 (HER2) on the prognosis of breast cancer patients treated with neoadjuvant chemotherapy (NCT). We investigated 110 patients with locally advanced breast cancer for ER, PR and HER2 status of their lesions before and after NCT. Results For hormone receptor status (HR) (which include ER, PR) of the residual tumor of the patients after receiving NCT, 12 (10.9%) of them changed from HR (+) to HR (−) and 15 (13.6%) changed from HR (−) to HR (+). For HER2 status after NCT, 8 (7.3%) patients changed from HER2 (+) to HER2 (−) and 9 (8.2%) patients changed from HER2 (−) to HER2 (+). Triple negative (TN) tumor phenotype changes occurred in 17 (15.5%) patients. Patients for whom the HR status changed from positive to negative had poor prognosis for both disease-free survival (DFS) and overall survival (OS) in univariate survival analysis. Conclusions Changes in ER, PR, HER2 status and tumor phenotype in breast cancer patients after NCT had a negative prognostic impact and were associated with a poor prognosis.","PeriodicalId":38592,"journal":{"name":"Forum of Clinical Oncology","volume":"12 1","pages":"3 - 11"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Forum of Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/fco-2019-0021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 1

Abstract

Abstract Background Introducing neoadjuvant chemotherapy (NCT) in a breast cancer patient may be associated with changes in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth hormone receptor 2 (HER2) status. Patients and methods In our prospective cohort study, we evaluated the impact of change in estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth hormone receptor 2 (HER2) on the prognosis of breast cancer patients treated with neoadjuvant chemotherapy (NCT). We investigated 110 patients with locally advanced breast cancer for ER, PR and HER2 status of their lesions before and after NCT. Results For hormone receptor status (HR) (which include ER, PR) of the residual tumor of the patients after receiving NCT, 12 (10.9%) of them changed from HR (+) to HR (−) and 15 (13.6%) changed from HR (−) to HR (+). For HER2 status after NCT, 8 (7.3%) patients changed from HER2 (+) to HER2 (−) and 9 (8.2%) patients changed from HER2 (−) to HER2 (+). Triple negative (TN) tumor phenotype changes occurred in 17 (15.5%) patients. Patients for whom the HR status changed from positive to negative had poor prognosis for both disease-free survival (DFS) and overall survival (OS) in univariate survival analysis. Conclusions Changes in ER, PR, HER2 status and tumor phenotype in breast cancer patients after NCT had a negative prognostic impact and were associated with a poor prognosis.

查看原文本刊更多论文

局部晚期乳腺癌新辅助化疗前后ER、PR、HER2新受体的一致性

摘要背景癌症患者采用新辅助化疗（NCT）可能与雌激素受体（ER）、孕酮受体（PR）和人表皮生长激素受体2（HER2）状态的变化有关。患者和方法在我们的前瞻性队列研究中，我们评估了雌激素受体（ER）、孕酮受体（PR）和人表皮生长激素受体2（HER2）的变化对接受新辅助化疗（NCT）的癌症患者预后的影响。我们调查了110例局部晚期癌症患者在NCT前后病变的ER、PR和HER2状态。结果NCT后残留肿瘤的激素受体状态（HR）（包括ER、PR），12例（10.9%）由HR（+）变为HR（−），15例（13.6%）由HR（−）变为HR（+）。对于NCT后的HER2状态，8名（7.3%）患者从HER2（+）变为HER2（−），9名（8.2%。17例（15.5%）患者出现三阴性（TN）肿瘤表型变化。在单变量生存分析中，HR状态从阳性变为阴性的患者的无病生存率（DFS）和总生存率（OS）预后较差。结论癌症患者NCT后ER、PR、HER2状态和肿瘤表型的变化对预后有负面影响，并与预后不良有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊